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Abstract 
 
Background:  
There remains a need to identify and validate biomarkers for predicting prostate 
cancer (CaP) outcomes using robust and routinely available pathology techniques to 
identify men at most risk of premature death due to prostate cancer. Previous 
immunohistochemical studies suggest the proliferation marker Ki67 might be a 
predictor of survival, independently of PSA and Gleason score. We performed a 
validation study of Ki67 as a marker of survival and disease progression and 
compared its performance against another candidate biomarker, DLX2, selected using 
artificial neural network (ANN) analysis. 
 
Methods: A tissue microarray (TMA) was constructed from transurethral resected 
prostatectomy (TURP) histology samples (n=192). ANN analysis was used to identify 
candidate markers conferring increased risk of death and metastasis in a public cDNA 
array. Immunohistochemical analysis of the TMA was carried out and univariate and 
multivariate tests performed to explore the association of tumour protein levels of 
Ki67 and DLX2 with time to death and metastasis.  
 
Results: Univariate analysis demonstrated Ki67 as predictive of CaP-specific survival 
(DSS; p=0.022), and both Ki67 (p=0.025) and DLX2 (p=0.001) as predictive of future 
metastases. Multivariate analysis demonstrated Ki67 as independent of PSA, Gleason 
score and D’Amico risk category for DSS (HR=2.436, p=0.029) and both Ki67 
(HR=3.296, p=0.023) and DLX2 (HR=3.051, p=0.003) as independent for future 
metastases.  
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Conclusion: High Ki67 expression is only present in 6.8% of CaP patients and is 
predictive of reduced survival and increased risk of metastasis, independent of PSA, 
Gleason score and D’Amico risk category. DLX2 is a novel marker of increased 
metastasis risk found in 73% patients and 8.2% showed co-expression with a high 
Ki67 score. Two cancer cell proliferation markers, Ki67 and DLX2, may be able to 
inform clinical decision making when identifying patients for active surveillance. 
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Introduction 
 
The last decade has seen the development and refinement of predictive risk 
stratification models in the management of prostate cancer (CaP) (Parekh et al., 
2006). These tools are validated for clinical decision-making and facilitating informed 
patient consent to treatment. 
 
These tools aim to apply an objective, evidence-based algorithm to a set of disease 
parameters, thus moving away from subjective judgments based on clinical 
experience. Unsurprisingly given the genetic and molecular heterogeneity between 
individuals, these tools are far from perfect. They cannot always determine an 
individual’s likelihood of clinically significant disease, particularly in classically low 
to intermediate risk groups, and in those patients undergoing active surveillance (AS) 
(Loeb et al., 2014; Wang et al., 2013).  Increased understanding of the molecular 
biology of CaP has identified some biomarkers that are predictive of disease outcome 
and therapeutic response to treatment (Ben-Porath et al., 2008), for complementary 
use with the serum PSA test and histological Gleason score assessment.  
 
The TransAtlantic Prostate Cancer Group developed a 31 gene cell cycle progression 
(CCP) signature for predicting outcome in prostate cancer (Cuzick et al., 2012, 2011) 
using  conservatively treated transurethral resected prostate (TURP) samples, and 
validated CCP in radical prostatectomy and initial needle core biopsy (Cuzick et al., 
2012). Another predictive test is the commercially available multigene RT-PCR 
Oncotype DX Prostate Cancer Assay. A 17-gene panel assesses markers of 4 distinct 
biological targets: the androgen pathway (AZGP1, KLK2, SRD5A2, and FAM13C), 
cellular organisation (FLNC, GSN, TPM2, and GSTM2), proliferation (TPX2) and 
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stromal response (BGN, COL1A1, and SFRP4), to produce a ‘genomic prostate 
score’ (GPS) that predicts the likelihood of high grade/stage disease at diagnosis 
(Klein et al., 2014; Knezevic et al., 2013).  
 
Cancer cell proliferation is a surrogate of tumour growth and is associated with 
worsened prognosis in prostate cancer and other cancer types (Ramsay et al., 2011), 
(Nagalla et al., 2013). Unsurprisingly, measuring the proportion of cancer cells 
undergoing cell proliferation using the immunohistochemical proliferation marker 
Ki67 has shown promise as a biomarker for predicting biochemical recurrence in 
patients with localised prostate cancer (Berney et al., 2009). In addition, Ki67 has 
been reported to predict distant metastasis formation in intermediate prostate cancer, 
following radiation therapy (Verhoven et al., 2013) and in conjunction with other 
markers post docetaxel chemotherapy (Antonarakis et al., 2012). It has also 
demonstrated predictive value in assessing overall survival (OS) and disease-specific 
survival (DSS) (Fisher et al., 2013). However there is a lack of consensus when 
assigning thresholds for dichotomously categorising patients, which have varied from 
2.4-26% for biochemical recurrence and from 3-10.3% for DSS. 
 
There remains an unmet need to identify markers capable of reliably assessing an 
individuals’ risk of developing metastasis and castrate resistance. These are important 
end-points for clinical assessment because they are associated with worsening 
prognosis. In this study we attempt to validate recent work carried out by Fisher et al 
in which they used a single biomarker, Ki67, to predict outcome in a conservatively 
managed group of patients diagnosed on needle core biopsy (Fisher et al., 2013). 
They demonstrated that Ki67 has significant ability to predict prostate cancer specific 
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death on both univariate and multivariate analysis (compared with PSA and Gleason 
Score). Ki67 has previously been demonstrated to predict survival and recurrence in 
patients undergoing radical treatment (Khor et al., 2009; Pollack et al., 2004; 
Zellweger et al., 2009). However Fishers work was the first study to demonstrate its 
prognostic utility from diagnostic biopsy in conservatively managed patients. This is 
important as this prognostic information could be used as an adjunct in clinical 
decision making to reduce the number of patients requiring radical treatment, with all 
its attendant risks. 
 
However Fisher’s group did not report whether Ki67 is predictive of metastasis. We 
therefore decided to examine the relationship between Ki67 expression and 
subsequent metastases and also applied a bioinformatic learning tool, Artificial Neural 
Network (ANN) analysis, to identify further biomarkers of metastasis development 
and DSS in a contemporary gene array library of an unselected population of prostate 
cancer patients.  
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Materials and Methods 
 
Patient selection and clinical data collection 
365 Patients diagnosed with CaP between 1999 and 2001 were identified. These were 
consecutive non-selected patients and all underwent ‘best-practice’ treatment at 
Nottingham City Hospital, UK. Initial histological cancer diagnosis was made using 
tissue obtained by prostate needle core biopsy or TURP specimens. A total of 192 
patients were selected for inclusion in the study; 155 patients were excluded to 
improve cohort homogeneity. Exclusion criteria included patients not undergoing 
TURP (29), patients lost to follow up or key parameters not recorded (114). Gleason 
scoring was modified in 2005 by the International Society of Urological Pathology 
(ISUP) consensus (Epstein et al., 2005) and for this reason all cases were 
histologically reviewed and Gleason scored using contemporary ISUP guidelines. 
Multiple clinicopathological variables were recorded for each patient including PSA 
and histological Gleason score at diagnosis, time taken to metastasis formation and 
time taken to prostate cancer specific death post-diagnosis. Patient management was 
based on PSA levels, histology Gleason score, and clinical staging. Patients were 
clinically followed-up at 3-6 monthly intervals and the majority of patients received 
‘watchful waiting’. Androgen deprivation therapy (ADT) was given for disease 
progression, indicated by a rapid rise in PSA level, symptoms or metastasis 
development. Palliative radiotherapy or chemotherapy was administered for symptom 
control (bone pain or prostate bleeding) in patients with late stage cancer.       
 
Use of the tissue samples for this study was approved by the North West 7 Research 
Ethics Committee – Greater Manchester Central REC number 10/H1008/72. 
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Tissue microarray (TMA) construction 
A TMA was constructed using archival wax-embedded TURP tissue samples sourced 
via the Nottingham Health Science BioBank. Histology sections were reviewed by a 
pathologist (GH) and 0.6mm diameter donor cores were sampled from at least two 
different tumour regions per patient using an automated TMA Grand Master 
instrument (3DHistech Ltd, Hungary).  
 
Biomarker selection 
ANN techniques were applied to a publically available prostate cancer cDNA gene 
expression array (Wang et al., 2010) to identify biomarkers for predicting tumour 
metastasis (Powe et al., 2014) so that their performance could be compared to the 
proliferation marker Ki67. We have previously reported on the use of an Artificial 
Neural Network technique to identify predictors of metastasis (Powe et al., 2014).  
Here the ANN model was reiterated 50 times with random sampling and the average 
mean square error of a test subset for each input variable was considered to determine 
the predictive capability for metastasis class. 
 
The top 10 genes ranked for association with metastasis development are 
included in Table 1. Four of these had commercially available antibodies 
(AMACR (Racemase), DLX2, PAICS and MYO6). DLX2 was selected for validation 
due to its novelty as a candidate marker in prostate cancer, its putative 
oncogenic function (Cantile et al., 2005; Morini et al., 2010), and its high ANN 
ranking.  For comparison, a curated literature search was performed to identify 
evidence for the application of Ki67 as a marker of outcome in prostate cancer 
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(Antonarakis et al., 2012; Berney et al., 2009; Fisher et al., 2013; Verhoven et al., 
2013) . 
 
Immunohistochemistry (IHC) 
Optimal antibody dilutions and antigen retrieval conditions were performed using 
positive and negative control tissues suggested by the antibody suppliers. After 
microwave antigen retrieval in 10mM sodium citrate slides were sequentially 
incubated in the primary antibody, detection reagents (Novolink, Leica), and 
haematoxylin.  
 
Immunostained TMA sections were assessed to determine the appropriate scoring 
technique for quantifying protein expression levels. Sections were independently 
scored (WG, DP) without knowledge of pathology grade. Ki67 and DLX2 nuclear 
staining was microscopically assessed at x20 magnification in tumour cells present in 
the TMA core, using a Histochemical score technique (H-score (McCarty et al., 
1985)). The H-score is achieved by summing the product of percentage cells showing 
each level of staining intensity where 0=absence of staining, 1=weak staining, 
2=moderate staining, and 3=strong staining intensity.  Staining thresholds used for 
dichotomous categorisation were chosen using the software program X-tile (Camp et 
al., 2004), or by those given in previously published studies. Patients were 
dichotomously categorised according to the nuclear H-score: positive expression was 
defined as a score equal to or greater than 110 for Ki67 and 10 for DLX2. 
 
We used REMARK guidelines (McShane et al., 2006) for reporting on prognostic 
biomarkers in the whole patient series. The proportion of patients with scorable tissue 
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sections was less than the total number of patients originally incorporated in the TMA 
due to detachment of cores during processing and because not every section taken 
from every core contained cancer tissue (independently reviewed by GH). Missing 
data was assessed for randomness using a Little’s test (Little, 1986) and Wilcoxon-
Mann-Whitney test, both at 95% confidence level. We failed to reject the null 
hypothesis of data being missing completely at random (p>0.05). The proportion of 
patients with tissue sections suitable for scoring is shown in Table 2.  
 
Statistical analysis 
Statistical analysis was performed using SPSS (Version 21; IBM, US) applied to 
verified cancer samples.  Pearson Chi-square tests were performed to assess 
biomarker associations with clinicopathological variables including initial PSA and 
Gleason score. Kaplan-Meier plots with log-rank tests were used to model biomarker 
associations with disease-specific survival (DSS; months) and time (months) to 
metastasis development from diagnosis. Biomarkers also underwent multivariate Cox 
proportional hazards regression modelling to assess the additional prognostic value to 
the initial PSA at diagnosis, Gleason score, and initial D’Amico risk category. The 
significance level used was P<0.05. If during biomarker analysis a particular 
clinicopathological variable was missing (for example if it had never been recorded in 
the notes) then that patient would be excluded from the statistical calculation.  
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Results 
 
Patient characteristics are shown in Table 3. Examples of nuclear Ki67 and DLX2 
staining are shown in Figure 1. 
 
Ki67 
A total 161/192/ (83.9%) patients samples had scorable tissue with 11 (6.8%) and 150 
(93.2%) showing positive and negative staining, respectively. Increased nuclear Ki67 
expression showed a negative association with OS (χ2=9.493, p=0.002) and DSS 
(χ2=5.222, p=0.022; Figure 2a) and a positive association with metastatic disease 
(χ2=5.058, p=0.025; Figure 2b). Subsequent multivariate Cox regression analysis 
demonstrated that Ki67 contributed additional predictive ability to PSA concentration, 
Gleason score and initial D’Amico risk for DSS (HR=2.436, p=0.029, 95%CI=1.096-
5.416) and metastasis risk (HR=3.296, p=0.023, 95%CI=1.1814-9.196). All Ki67 
positive patients had high grade cancer (Gleason score 8-10, Groups 4-5) and in 
addition, 8/11 (72.7%) Ki67 positive patients showed co-expression with DLX2.   
 
DLX2 
A total 185/192 patients samples had scorable tissue with 135 (73%) and 50 (27%) 
showing positive and negative staining, respectively. DLX2 expression was not 
associated with Gleason score or PSA levels. DLX2 alone was not found to be 
predictive of DSS (χ2=2.282, p=0.131) (Figure 2c) but increased nuclear DLX2 
expression showed a positive association with metastasis development (χ2=10.207, 
p=0.001; Figure 2d), independent of PSA concentration, Gleason score and initial 
D’Amico risk using multivariate Cox regression analysis (HR=2.754, p=0.003, 
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95%CI=1.423-5.332)..  Coexpression with high Ki67 staining was seen in 8.2% 
DLX2 positive tumours.  
 
Discussion 
This study compares the utility of two biomarkers to predict prostate cancer survival 
and risk of metastasis in an unselected cohort of prostate cancer patients with at least 
ten years of clinical follow up. Biomarker selection was based on recent studies 
highlighting Ki67 as a marker of cell proliferation and outcome in prostate cancer 
(Antonarakis et al., 2012; Berney et al., 2009; Khor et al., 2009; Pollack et al., 2004; 
Verhoven et al., 2013; Zellweger et al., 2009)  and a bioinformatic ANN approach 
applied to a gene expression array derived from prostate cancer patients, interrogated 
for markers of metastases. Development of metastasis was associated with increased 
expression of the tumour markers Ki67 and DLX2. To the best of our knowledge this 
is the first study of DLX2 being used as a marker of disease progression in prostate 
cancer. Interestingly co-expression of Ki67 and DLX2 occurred in 6.8%(11/161) 
scorable patients and was characterised by high cancer grade (Gleason 8-10) and high 
risk of metastasis.  
 
Ki67 is functionally associated with cellular proliferation and is a surrogate for the 
growth fraction of tumours. It has been reported to be predictive of CaP specific 
mortality (Antonarakis et al., 2012; Verhoven et al., 2013; Zellweger et al., 2009) and 
we confirm that Ki67  provides prognostic information on disease-specific and overall 
survival in prostate cancer. Furthermore, we demonstrated that Ki67 provides 
additional prognostic utility (HR:2.19) to the PSA and Gleason score, validating the 
study by Fisher et al. (Fisher et al., 2013) who recently reported that Ki67 from 
biopsy tissue independently predicts survival in prostate cancer (HR:2.78).   
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In addition to validating Fishers work we also demonstrated that Ki67 expression is 
predictive of future metastases in prostate cancer, adding to the small but growing 
cohort of potential markers of metastasis in this disease. For example, recent work by 
Columbel et al has examined the expression of three putative stem cell markers 
(integrin alpha 2 and 6 and CMET) in men with high risk CaP. They concluded that 
the proportion of stem cell-like cancer cells is predictive of bone metastases. 
 
Interestingly only 6.8% (11 patients) of our cancer cohort had a significantly raised 
Ki67 and we propose that such patients could be counselled regarding an increased 
risk of death and metastasis, particularly if they are also positive for DLX2, and 
should be considered for an active surveillance programme. Both markers are known 
to be functionally important in cancer cell proliferation and, coupled with their 
association with high Gleason grade reported here, these findings fit with a hypothesis 
that tumour proliferation rates are a surrogate for tumour aggression and poor 
prognosis. 
 
Using an Artificial Neural Networking approach DLX2 was identified as a marker for 
metastasis prediction. The distal-less homeobox (DLX) gene family are involved in 
embryonic development, tissue homeostasis, cell cycle and apoptosis (Tang et al., 
2013). A growing number of homeobox genes have been shown to be deregulated in a 
variety of human tumors, and their deregulation is known to enhance cell survival and 
proliferation and prevent differentiation (Lee et al., 2011). Aberration is reported in 
breast, lung, ovarian and colon tumours (Morini et al., 2010) and early work has 
shown that these genes may be involved in neuroendocrine differentiation seen in 
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advanced prostate cancers (Cantile et al., 2005) but no association with clinical 
outcomes has ever been reported.   
 
DLX2  has been reported to be  involved in shifting TGFβ from a tumour suppressor 
to a tumour promoting function by repressing TGFβRII and the cell cycle inhibitor 
p21CIP1, and simultaneously increasing the mitogenic transcription factor c-Myc and 
epidermal growth factor (EGF) (Yilmaz et al., 2011). In addition it has been 
suggested that DLX2 activity may suppress TGFbeta-mediated cell adhesion and 
migration inhibition (Massagué, 2008). Our novel DLX2 findings validate the ANN 
bioinformatics approach in revealing it to be a strong predictor of increased metastasis 
risk (HR:3.311), more so than either the PSA or Gleason score. DLX2 therefore 
warrants further investigation because of its ability to assess cancer cell survival 
potential. 
 
In summary, we demonstrate that two cell proliferation markers, Ki67 and DLX2, 
appear to predict CaP specific survival and metastasis. Independent validation of 
these findings is needed to establish if Ki67 and DLX2 (specially co-expression) 
should be considered for prospective clinical trials. 
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Titles and Legends to Figures 
 
Figure 1: Examples of positive Ki67 (a) and DLX2 (b) nuclear prostate cancer 
staining compared to tumours that did not express Ki67 (c) or DLX2 (d) 
 
Figure 2: Kaplan–Meier plots demonstrating a) Prostate specific cancer death over 
time according to Ki-67 score; b) Metastasis development over time according to Ki-
67 score; c) Prostate specific cancer death over time according to DLX2 score d) 
Metastasis development over time according to DLX2 score. 
 
 
 
Table 1: ANN ranked gene list showing association with prostate cancer metastasis  
 
Table 2: The number of patients within the prostate cancer cohort that were 
dichotomously categorised for each biomarker 
 
Table 3: Characteristics of prostate cancer patients incorporated in the TMA 
 
Table 4: Multivariate analysis was performed to assess the predictiveness of Ki67 
and DLX2 compared to PSA concentration, Gleason groups and D’Amico risk.  
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Tables 1-4 
 
Table 1 
Rank Gene accession number Gene name Gene Product (protein)
 
1 AK022765.1 AMACR Alpha-methylacyl-CoA 
racemase 
2 AI796120 AMACR Alpha-methylacyl-CoA 
racemase 
3 AF047020.1 AMACR Alpha-methylacyl-CoA 
racemase 
4 NM_004405.2 DLX2 Distal-less homeo box 2
5  PCA3 Prostate cancer antigen 3
6 NM_012485.1 HMMR Hyaluronan-mediated 
motility receptor 
(RHAMM or CD168) 
7 U90236.2 MYO6 Myosin VI 
8 NM_017636.1 FLJ20041 Hypothetical protein 
FLJ20041 
Alias: TRPM4B 
9 BF511718 RHO7 GTP-binding protein 
Rho7 
Alias: RND2 
10 NM_006452.1 ADE2H1 Multifunctional 
polypeptide similar to 
SAICAR synthetase and 
AIR carboxylase 
Alias: PAICS 
11 NM_002570.1 PACE4 Paired basic amino acid 
cleaving system 
12 NM_004503.1 HOXC6 Homeo box C6 
 
 
 
 
 
 
 
 
 
Table 2 
Biomarker (score) Number of cancer 
patients scored 
Number positive (%) Number negative (%)
Ki67 (>110) 161 11 (6.8) 150 (93.2) 
DLX2 (>10) 185 135 (73) 50 (27) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
Clinical 
variable 
 Number 
of 
patients 
(%) 
Chemotherapy Androgen 
depletion 
therapy 
including 
orchidectomy 
(% all 
patients) 
Radiotherapy
(% all 
patients) 
    
PSA (ng/ml) 
at diagnosis 
≤4 18 (9.4)  
 >4 168 
(87.5) 
 
 Not 
recorded 
6 (3.125)  
    
Gleason 
Score 
Group 1: ≤6 7 (3.6) 1 (0.52) 6 (3.1) 0 
 Group 2: 
3+4 
22 (11.5) 5 (2.6) 4 (2) 0 
 Group 3: 
4+3 
31 (16.1) 5 (2.6) 6 (3.1) 2 (1) 
 Group 4: 8 42 (21.9) 9 (4.7) 8 (4.1) 0 
 Group 5: 9-
10 
90 (46.9) 43 (22.4) 30 (15.6) 3 (1.5) 
    
Metastasis At diagnosis 32 (16.6)  
 Subsequent 
metastasis 
73 (38)  
 Never 
developed 
metastasis 
87 (45.3)    
    
    
Death due 
to prostate 
cancer 
Yes 105 
(54.7) 
 
 No  55 (28.6)  
 Still alive 20 (10.4)  
 Not 
recorded 
12 (6.2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 
   95% Confidence interval  
Variable Significance Hazard ratio Lower Upper
Ki67 Survival prediction 
Ki67 0.029 2.436 1.096 5.416
PSA 
concentration 
0.290 1.00 1.000 1.000
Gleason 
categories 
0.936 1.018 0.659 1.572 
D’Amico risk 0.964 0.919 0.347 2.433
 
Ki67 Metastasis prediction 
Ki67 0.023 3.296 1.181 9.196
PSA 
concentration 
0.131 1.001 1.000 1.002
Gleason 
categories 
0.146 1.469 0.874 2.469
D’Amico risk 0.325 0.600 0.217 1.660
 
DLX2 Metastasis prediction 
DLX2 0.003 3.051 1.451 6.418
PSA 
concentration 
0.202 1.002 0.999 1.004
Gleason 
categories 
0.768 1.081 0.643 1.819
D’Amico risk 0.827 0.891 0.316 2.511
 
